Blood cancer research may lead to new treatments


At this year’s American Society of Hematology Annual Meeting, Dana-Farber scientists presented major findings that could one day improve diagnosis and treatment of blood cancers, extend life, or even cure some diseases.

Among the highlights:

Steven Treon, MD, PhD, and his colleagues identified a gene mutation that underlies the vast majority of cases of Waldenström’s macroglobulinemia, a rare form of non-Hodgkin lymphoma. The results suggest that new, effective treatments are now possible for people with Waldenström’s. Read more about Dr. Treon’s Waldenström’s macroglobulinemia research breakthrough.

Catherine J. Wu, MD, co-led investigators who discovered nine new gene mutations that could help doctors predict if and how chronic lymphocytic leukemia (CLL) will progress, and lead to new treatments for CLL. Take a closer look at Dr. Wu’s CLL research.

Corey Cutler, MD, MPH, and his colleagues reported on a new clinical trial that may improve the ability of stem cells from umbilical cord blood to take root in patients receiving a stem cell transplant more quickly and with a higher degree of success. Learn more about Dr. Cutler’s stem cell transplant clinical trial.

Comments Sort By Newest

Leave a Reply

Your email address will not be published. Required fields are marked *

Blue Captcha Image


Latest Tweets

Dana-Farber @danafarber
The Latest in Lung Cancer Treatment and Research: #lcsm
Dana-Farber @danafarber
Join us Dec. 15 to discuss the latest in prostate cancer research: #dfciwebchat
Dana-Farber @danafarber
Watch Dr. Pomerantz discuss the latest in #prostatecancer research, prevention & treatment on 12/15: #DFCIwebchat

Make An Appointment

For adults: 877-442-3324

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.